Population-based pharmacokinetic modeling of perfluoroalkyl substances

Matthew MacLeod & Malicka Laroussi

Kathleen Attfield

Roland Ritter, Ian Cousins, Fiona Wong, Melissa Gomis, Qingwei Bu, Martin Scheringer, Kevin C. Jones & Jochen Mueller

We all have chemicals in our bodies...

The balance between exposure and elimination determines how much!















Characterized as a first-order process using an estimated elimination half-life



$$\frac{dc(t)}{dt} = -(k_{\text{elim}} + k_{\text{growth}}) \cdot c(t) + \frac{I_{\text{diet}}(t) \cdot f}{m_{\text{lip}}}$$





 Model representative individuals born every year for a century to create a populationbased pharmacokinetic model...

9 individuals, one born every 10 years starting in 1931





Complete information

1280 VOLUME 117 | NUMBER 8 | August 2009 · Environmental Health Perspectives Research A Multi-Individual Pharmacokinetic Model Framework for Interpreting Time Trends of Persistent Chemicals in Human Populations: Application to a Postban Situation Roland Ritter, Martin Scheringer, Matthew MacLeod, Urs Schenker, and Konrad Hungerbühler Safety and Environmental Technology Group, ETH Zurich, Zurich, Switzerland in exposure (UNEP 2007; World Health BACKGROUND: Human milk and blood are monitored to detect time trends of persistent organic Organization 2007). The second factor that pollutants (POPs) in humans. It is current practice to use log-linear regression to fit time series of has been reported to influence CSTD-based averaged cross-sectional biomonitoring data, here referred to as cross-sectional trend data (CSTD). half-lives is the rate of elimination of a sub-OBJECTIVE: The goals of our study are to clarify the interpretation of half-lives derived from fitting stance from the body by all possible pathways.

Environmental Health Perspectives · VOLUME 119 | NUMBER 2 | February 2011

225 Research

Intrinsic Human Elimination Half-Lives of Polychlorinated Biphenyls Derived from the Temporal Evolution of Cross-Sectional Biomonitoring Data from the United Kingdom

Roland Ritter,¹ Martin Scheringer,¹ Matthew MacLeod,¹ Claudia Moeckel,² Kevin C. Jones,² and Konrad Hungerbühler¹

¹Safety and Environmental Technology Group, ETH Zurich, Zurich, Switzerland; ²Lancaster Environment Centre, Lancaster University, Lancaster, United Kingdom

BACKGROUND: Most empirical estimates of human elimination kinetics for persistent chemicals reflect apparent elimination half-lives that represent the aggregated effect of intrinsic elimination, ongoing exposure, and changes in body weight. However, estimates of intrinsic elimination at back-

substances range from < 1 year to several decades, and even negative values have been reported (Matsumoto et al. 2009; Milbrath et al. 2009: Shirai and Kissel 1996). We use

PFOS (Perfluorooctane sulfonate) is the most abundant POP measured in humans



NHANES = National Health and Nutrition Examination Survey

Could loss of PFOS by menstruation explain the different body burdens in women and men?

Our population-based model is based on an intrinsic elimination rate constant (k_{elim})

$$\frac{dc(t)}{dt} = -(k_{\text{elim}} + k_{\text{growth}}) \cdot c(t) + \frac{I_{\text{diet}}(t) \cdot f}{m_{\text{lip}}}$$

- Chemical specific
- Constant regardless of one's sex, age, body weight, ongoing exposure, and physiology

Add a new process to the model...

- Introduce a new term to describe losses with menstrual blood (Gmenstrual blood loss / VD)
- V_D Volume of distribution (mL/kg)
 - $C_{whole-body} (ng/kg) / C_{blood} (ng/mL)$



Population-based Pharmacokinetic Model



NHANES = National Health and Nutrition Examination Survey

Results – PFOS in the US population



Men, modeled – HL 5.5 years
 Women (*non-menstruating*), modeled – HL 4.3 years
 Women (*menstruating*), modeled – HL 4.9 years

When menstruation is modeled as a sex & age specific loss process the difference in k_{elim} between women and men is *almost* gone!



PFOS half-lives in the US population (years)

Could loss of PFOS by menstruation explain the different body burdens in women and men?

Yes.

Assuming the same body-weight normalized intake, the model fits data for women just as well as for men when menstruation is included

Could loss of PFOS by menstruation explain the different body burdens in women and men?



Could loss of PFOS by menstruation explain the different body burdens in women and men?

Yes.

Assuming the same body-weight normalized intake, the model fits data for women just as well as for men when menstruation is included

But...

Modeled k_{elim} for women still did not convincingly overlap with k_{elim} for men...



Article

pubs.acs.org/est

Enhanced Elimination of Perfluorooctane Sulfonic Acid by Menstruating Women: Evidence from Population-Based Pharmacokinetic Modeling

Fiona Wong,*,[†] Matthew MacLeod,[†] Jochen F. Mueller,[§] and Ian T. Cousins[†]

[†]Department of Applied Environmental Science (ITM), Stockholm University, Svante Arrhenius väg 8, SE-10691, Stockholm, Sweden

[§]National Research Centre for Environmental Toxicology, The University of Queensland, 39 Kessels Road, Coopers Plains, Queensland 4108, Australia

Supporting Information

ABSTRACT: Human biomonitoring studies have shown that concentrations of perfluorooctane sulfonic acid (PFOS) in men are higher than in women. We investigate sex differences in elimination of PFOS by fitting a population-based pharmacokinetic model to six cross-sectional data sets from 1999 to 2012 from the US National Health and Nutrition Examination Survey

(NHANES) and derive human first-order elimination rate cor corresponding elimination half-lives $(t_{1/2})$ for PFOS, where $t_{1/2}$ use a modified version of the Ritter population-based pharma and derive elimination rate constants separately for men an model accounts for population-average lifetime changes in PFG weight, and menstruation rate. We compare the model-deri rate constant for hypothetical nonmenstruating women to the







pubs.acs.org/est

Response to Comment on "Enhanced Elimination of Perfluorooctane Sulfonic Acid by Menstruating Women: Evidence from Population-based Pharmacokinetic Modeling"

We thank Verner and Longnecker¹ for their insightful comments on the rate of menstrual blood serum loss $(G_{\rm mbb}, {\rm mL/kg-bw/year})$. We agree with the authors that the parameter $G_{\rm mbl}$ is subject to uncertainty and that there are limited literature available for characterizing the composition and volume of menstrual fluid loss.

In our paper,² we assumed that monthly menstrual blood serum loss is 36 mL/month, which amounts to 432 mL/year and $G_{\rm mbl} = 6.1$ mL/kg-bw/year, assuming a body weight of 71 kg. During our uncertainty and sensitivity analysis, we assigned

difference in the elimination rate of PFOS between men and women. Figure 1 shows the modeled data fits well to the measured data when the adjusted G_{mbl} is applied. When we plotted the modeled vs measured data using the adjusted G_{mbl} , the root mean squared error (RMSE) = 0.04, which is smaller than the RMSE estimated from the G_{mbl} of Wong et al.,² that is, 0.05.

Finally, we acknowledge the lack of information for parametrizing G_{mbl} and are therefore grateful for Verner and Longnecker's¹ contribution. In the absence of even newer

2022 – Update PFOS & model other PFAS

- 1) New NHANES data for 2011, 2013 and 2015, and 1999 data retracted (!)
- 2) Assume menstrual blood loss accounts for difference between men & women and treat $V_{\rm D}$ as a fitting parameter







Intrinsic elimination half-life Men: 4.3 years Women: 4.0 years

 $V_{\rm D}$: 256 mL/kg





5 10 15 20 25 30 Measured PFOS concentration in serum (ng/mL)

0 +

10

5

15

Measured PFOS concentration in serum (ng/mL)

20

25

30





Women

Measured PFOA concentration in serum (ng/mL)

Men

Measured PFOA concentration in serum (ng/mL)

 $V_{\rm D}$: 261 mL/kg





Intrinsic elimination half-life Men: 4.1 years Women: 3.8 years

V_D: 305 mL/kg





Intrinsic elimination half-life Men: 4.1 years Women: 3.8 years

V_D: 305 mL/kg







Intrinsic elimination half-life Men: 5.0 years Women: 5.0 years

*V*_D: 590 mL/kg







Intrinsic elimination half-life Men: 5.0 years Women: 5.0 years

*V*_D: 590 mL/kg



Men, empirical US NHANES
 Men, modeled
 Women, empirical US NHANES
 Women, modeled





Intrinsic elimination half-life Men: 4.9 years Women: 5.2 years

V_D: 412 mL/kg

PFUdA







Intrinsic elimination half-life Men: 4.9 years Women: 5.2 years

*V*_D: 412 mL/kg







Intrinsic elimination half-life Men: 4.3 years Women: 3.9 years

*V*_D: 84 mL/kg







Intrinsic elimination half-life Men: 4.3 years Women: 3.9 years

*V*_D: 84 mL/kg

Summary - $V_{\rm D}$

Compound	Modeled human volume of distribution (V ^D) mL/kg	Reported volume of distribution (VD), study mL/kg
PFOS	256	230 human (Thompson, et al., 2010)
		274 (+/- 28) female monkeys, (<i>Chang et al. 2012</i>)
PFOA	261	170 human (Thompson, et al., 2010)
		198 (+/- 69) female monkeys (<i>Butenhoff et al. 2004</i>)
PFNA	305	243 (+/-49) female rat (Ohmori et al. 2003) 46 (+/- 4) female rat <i>(Kim et al. 2019)</i>
PFHxS	84	213 (+/- 28) female monkeys. (<i>Sundström et al, 2012</i>)
PFDA	591	441 (+/- 55) female rats (Ohmori et al. 2003)
PFUdA	412	250 (+/- 80) female rats (<i>Fuji et al. 2015</i>)

Summary - $V_{\rm D}$

Compound	Modeled human volume of distribution (V ^D) mL/kg	Reported volume of distribution (VD), study mL/kg
PFOS	256	230 human (Thompson, et al., 2010)
		274 (+/- 28) female monkeys, (<i>Chang et al. 2012</i>)
PFOA	261	170 human (Thompson, et al., 2010)
		198 (+/- 69) female monkeys (<i>Butenhoff et al. 2004</i>)
PFNA	305	243 (+/-49) female rat (Ohmori et al. 2003) 46 (+/- 4) female rat <i>(Kim et al. 2019)</i>
PFHxS	84	213 (+/- 28) female monkeys. (Sundström et al, 2012)
PFDA	591	441 (+/- 55) female rats (Ohmori et al. 2003)
PFUdA	412	250 (+/- 80) female rats (<i>Fuji et al. 2015</i>)
	Highly u	Incertain – No "signal" to model

Summary - $V_{\rm D}$

Modeled human volume of

distribution (V_D)

mL/kg

256

261

305

Compound

PFOS

PFOA

PFNA

Also a modeling study! Reported volume of distribution (VD), study mL/kg 230 human (Thompson, et al., 2010) 274 (+/- 28) female monkeys, (*Chang et al. 2012*) 170 human (Thompson, et al., 2010)

198 (+/- 69) female monkeys (*Butenhoff et al. 2004*)

243 (+/-49) female rat (Ohmori et al. 2003) 46 (+/- 4) female rat (*Kim et al. 2019*)

 PFHxS
 84
 213 (+/- 28) female monkeys. (Sundström et al, 2012)

 PFDA
 591
 441 (+/- 55) female rats (Ohmori et al. 2003)

 PFUdA
 412
 250 (+/- 80) female rats (Fuji et al. 2015)

Highly uncertain – No "signal" to model

2022 – Model CARES Biomonitoring Data

1) 2018 – LA County 400 serum samples

California Regional Exposure Study

2019 – Southern California
 350 serum samples

















Modeling CARES Data

- We assumed $V_{\rm D}$ and $k_{\rm elim}$ from the NHANES population would also apply to the CARES populations
- Tested the hypothesis that intake of PFAS by the CARES populations was different than NHANES...

- No obvious evidence of that!

Conclusions

- New population-based pharmacokinetic modeling of NHANES biomonitoring data for 6 PFAS provides estimates of
 - Intake levels and trends
 - Intrinsic elimination half-lives (k_{elim})
 - Volumes of distribution (V_D)

Acknowledgments

- Swiss Federal Office for the Environment
- FORMAS



ADVANCED TOOLS FOR EXPOSURE ASSESSMENT AND BIOMONITORING





Even better with the correct composition of menstrual blood!

